Kamidam

Aripiprazole, the active ingredient in Kamidam, is an atypical antipsychotic presented as an oral tablet for oral administration. It is used to manage schizophrenia, bipolar I disorder (manic or mixed episodes) and as adjunctive therapy for major depressive disorder in adults. It is approved for adult patients and is available in the European Union market, offering a therapeutic option with a favorable efficacy profile.

GNH USA supplies Kamidam as a licensed, GDP‑compliant international pharmaceutical supplier, meeting EU quality standards and serving hospitals, pharmacies and clinics worldwide with reliable, on‑time delivery.

Aripiprazole is indicated for several psychiatric conditions that involve dysregulation of dopamine and serotonin pathways.

- Schizophrenia: reduces hallucinations, delusions and thought disorder while improving overall social and occupational functioning. - Bipolar I disorder (manic or mixed episodes): stabilizes mood, decreases the frequency and severity of manic episodes, and helps maintain long‑term mood balance. - Major depressive disorder (adjunctive): enhances the efficacy of standard antidepressants, leading to greater improvement in depressive symptoms when used as an add‑on therapy.

Aripiprazole may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Akathisia: inner restlessness, an urge to move constantly, often accompanied by anxiety. - Insomnia: difficulty falling asleep or staying asleep, leading to daytime fatigue. - Nausea: mild to moderate stomach upset, sometimes with vomiting. - Headache: transient cranial pain that may vary in intensity.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with high fever, muscle rigidity and autonomic instability. - Tardive dyskinesia: persistent involuntary movements of the tongue, lips or facial muscles, potentially irreversible. - Suicidal thoughts: emergence or worsening of suicidal ideation, requiring prompt clinical evaluation.

When prescribing aripiprazole, clinicians should consider several precautionary measures to ensure safe use.

- Assess psychiatric history: evaluate prior response to antipsychotics and risk of relapse. - Monitor metabolic parameters: regularly check weight, glucose and lipid levels due to possible metabolic effects. - Evaluate cardiovascular status: observe for orthostatic hypotension and QT prolongation, especially in at‑risk patients. - Review concomitant medications: avoid drugs that strongly inhibit CYP2D6 or CYP3A4 which may increase aripiprazole exposure. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at ambient temperature: keep tablets below 25 °C in the original container, protect from moisture and light.

Aripiprazole can interact with other medicines, altering its plasma concentration or increasing adverse effect risk.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise aripiprazole levels, increasing toxicity risk. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may lower aripiprazole exposure, reducing efficacy. - Monoamine oxidase inhibitors: concurrent use can precipitate hypertensive crisis or serotonin syndrome.

Moderate Interactions (Monitor Closely): - Other antipsychotics: combined use may enhance central nervous system depression and extrapyramidal symptoms. - Antihypertensives: aripiprazole may attenuate blood pressure‑lowering effects. - Sedatives/hypnotics: additive sedation may occur, requiring dose adjustments.